Literature DB >> 29557918

Aerobic Exercise During Early Murine Doxorubicin Exposure Mitigates Cardiac Toxicity.

Fei Wang1, Brian Iskra2, Eugenie Kleinerman1, Claudia Alvarez-Florez1, Thomas Andrews2, Angela Shaw1, Joya Chandra1, Keri Schadler1, Gregory J Aune2,3.   

Abstract

We report the cardioprotective effects of moderate aerobic exercise from parallel pediatric murine models of doxorubicin (Doxo) exposure in non-tumor-bearing immune competent (NTB-IC) mice and tumor-bearing nude mice (TB-NM). In both models, animals at 4 weeks of age underwent Doxo treatment with or without 2 weeks of simultaneous exercise. In sedentary NTB-IC or TB-NM mice, Doxo treatment resulted in a statistically significant decrease in ejection fraction and fractional shortening compared with control animals. Interestingly, moderate aerobic exercise during Doxo treatment significantly mitigated decreases in ejection fraction and fractional shortening. In contrast, these protective effects of exercise were not observed when exercise was started after completion of Doxo treatments. Moreover, in the TB-NM model, Doxo caused a decrease in heart mass: tibia length and in body weight that was prevented by exercise, whereas NTB-IC mice exhibited no change in these measurements. Doxo delivery to the hearts of TB-NM was decreased by consistent moderate aerobic exercise before Doxo injection. These findings demonstrate the important but subtle differences in cardiotoxicity observed in different mouse models. Collectively, these results also strongly suggest that aerobic exercise during early-life Doxo exposure mitigates cardiotoxicity, possibly through altered delivery of Doxo to myocardial tissue.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29557918      PMCID: PMC6876617          DOI: 10.1097/MPH.0000000000001112

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  35 in total

Review 1.  Mechanisms of exercise-induced cardioprotection.

Authors:  Scott K Powers; Ashley J Smuder; Andreas N Kavazis; John C Quindry
Journal:  Physiology (Bethesda)       Date:  2014-01

2.  Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.

Authors:  Gregory T Armstrong; Kevin C Oeffinger; Yan Chen; Toana Kawashima; Yutaka Yasui; Wendy Leisenring; Marilyn Stovall; Eric J Chow; Charles A Sklar; Daniel A Mulrooney; Ann C Mertens; William Border; Jean-Bernard Durand; Leslie L Robison; Lillian R Meacham
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

3.  Exercise preconditioning provides long-term protection against early chronic doxorubicin cardiotoxicity.

Authors:  David S Hydock; Chia-Ying Lien; Brock T Jensen; Carole M Schneider; Reid Hayward
Journal:  Integr Cancer Ther       Date:  2011-03-07       Impact factor: 3.279

Review 4.  Anthracycline-induced cardiotoxicity.

Authors:  K Shan; A M Lincoff; J B Young
Journal:  Ann Intern Med       Date:  1996-07-01       Impact factor: 25.391

5.  Pretreatment effect of running exercise on HSP70 and DOX-induced cardiotoxicity.

Authors:  Vahid Shirinbayan; Valiollah Dabidi Roshan
Journal:  Asian Pac J Cancer Prev       Date:  2012

6.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

7.  Concomitant low-dose doxorubicin treatment and exercise.

Authors:  Kathleen Sturgeon; Keri Schadler; Geetha Muthukumaran; Dennis Ding; Akinyemi Bajulaiye; Nicholas J Thomas; Victor Ferrari; Sandra Ryeom; Joseph R Libonati
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2014-07-09       Impact factor: 3.619

8.  Clinical ascertainment of health outcomes among adults treated for childhood cancer.

Authors:  Melissa M Hudson; Kirsten K Ness; James G Gurney; Daniel A Mulrooney; Wassim Chemaitilly; Kevin R Krull; Daniel M Green; Gregory T Armstrong; Kerri A Nottage; Kendra E Jones; Charles A Sklar; Deo Kumar Srivastava; Leslie L Robison
Journal:  JAMA       Date:  2013-06-12       Impact factor: 56.272

Review 9.  Physical exercise training interventions for children and young adults during and after treatment for childhood cancer.

Authors:  Katja I Braam; Patrick van der Torre; Tim Takken; Margreet A Veening; Eline van Dulmen-den Broeder; Gertjan J L Kaspers
Journal:  Cochrane Database Syst Rev       Date:  2013-04-30

Review 10.  Doxorubicin: the good, the bad and the ugly effect.

Authors:  Cristina Carvalho; Renato X Santos; Susana Cardoso; Sónia Correia; Paulo J Oliveira; Maria S Santos; Paula I Moreira
Journal:  Curr Med Chem       Date:  2009-09-01       Impact factor: 4.530

View more
  18 in total

Review 1.  Doxorubicin-Induced Cardiomyopathy in Children.

Authors:  Trevi R Mancilla; Brian Iskra; Gregory J Aune
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

Review 2.  Can Exercise-Induced Modulation of the Tumor Physiologic Microenvironment Improve Antitumor Immunity?

Authors:  Xiaojie Zhang; Kathleen A Ashcraft; Allison Betof Warner; Smita K Nair; Mark W Dewhirst
Journal:  Cancer Res       Date:  2019-05-08       Impact factor: 12.701

3.  Development and characterization of a mass cytometry panel for detecting the effect of acute doxorubicin exposure on murine cardiac nonmyocytes.

Authors:  Brian S Iskra; Logan Davis; Henry E Miller; Yu-Chiao Chiu; Alexander J R Bishop; Yidong Chen; Gregory J Aune
Journal:  Am J Physiol Heart Circ Physiol       Date:  2022-06-03       Impact factor: 5.125

Review 4.  Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.

Authors:  Nonniekaye Shelburne; Naoko I Simonds; Bishow Adhikari; Michael Alley; Patrice Desvigne-Nickens; Eileen Dimond; Kelly Filipski; Lisa Gallicchio; Lori Minasian
Journal:  Curr Oncol Rep       Date:  2019-01-30       Impact factor: 5.075

Review 5.  Exercise and Physical Activity in Patients with Osteosarcoma and Survivors.

Authors:  Miriam B Garcia; Kirsten K Ness; Keri L Schadler
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

6.  Elimination of endogenous high molecular weight FGF2 prevents pressure-overload-induced systolic dysfunction, linked to increased FGFR1 activity and NR1D1 expression.

Authors:  Navid Koleini; Barbara E Nickel; Raghu S Nagalingam; Natalie M Landry; Robert R Fandrich; David Y C Cheung; Ian M Dixon; Michael P Czubryt; Davinder S Jassal; Peter A Cattini; Elissavet Kardami
Journal:  Cell Tissue Res       Date:  2021-05-31       Impact factor: 5.249

Review 7.  Cardiomyocyte Atrophy, an Underestimated Contributor in Doxorubicin-Induced Cardiotoxicity.

Authors:  De-Shu Chen; Jing Yan; Ping-Zhen Yang
Journal:  Front Cardiovasc Med       Date:  2022-02-25

Review 8.  Clinical and preclinical evidence of sex-related differences in anthracycline-induced cardiotoxicity.

Authors:  Becky Meiners; Chetan Shenoy; Beshay N Zordoky
Journal:  Biol Sex Differ       Date:  2018-08-29       Impact factor: 5.027

Review 9.  Nanomedicine in Oncocardiology: Contribution and Perspectives of Preclinical Studies.

Authors:  Gabriel Silva Marques Borges; Eduardo Burgarelli Lages; Pierre Sicard; Lucas Antônio Miranda Ferreira; Sylvain Richard
Journal:  Front Cardiovasc Med       Date:  2021-06-30

Review 10.  TRPC channels in exercise-mimetic therapy.

Authors:  Takuro Numaga-Tomita; Sayaka Oda; Kazuhiro Nishiyama; Tomohiro Tanaka; Akiyuki Nishimura; Motohiro Nishida
Journal:  Pflugers Arch       Date:  2018-10-08       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.